Michaela Liedtke
Experienced in MAGIC Syndrome

Dr. Michaela Liedtke

Hematology | Oncology
300 Pasteur Dr, 
Stanford, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in MAGIC Syndrome
300 Pasteur Dr, 
Stanford, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michaela Liedtke is a Hematologist and an Oncologist in Stanford, California. Dr. Liedtke is rated as an Experienced provider by MediFind in the treatment of MAGIC Syndrome. Her top areas of expertise are Primary Amyloidosis, Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 119 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Stanford Health Care Tri-Valley
Renown Regional Medical Center
Dominican Hospital
Stanford Health Care
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

STANFORD HEALTH CARE
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Enrollment Status: Recruiting
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Suspended
Publish Date: September 05, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Enrollment Status: Active_not_recruiting
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drugs: Daratumumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: SEA-BCMA, Dexamethasone, Pomalidomide
Study Phase: Phase 1
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: AO-176, AO-176 + Dex, AO-176 + Dex + Bort
Study Phase: Phase 1/Phase 2
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Vincristine sulfate, Prednisone, Inotuzumab ozogamicin
Study Phase: Phase 1
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (VXLD) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia
A Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy (VXLD) for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia
Enrollment Status: Completed
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia
A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: May 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 11 Less Clinical Trials

119 Total Publications

NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 09, 2025
Similar Doctors
Experienced in MAGIC Syndrome
Dr. Milana V. Dolezal
Oncology | Hematology
Experienced in MAGIC Syndrome
Dr. Milana V. Dolezal
Oncology | Hematology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Milana Dolezal is an Oncologist and a Hematologist in Stanford, California. Dr. Dolezal is rated as a Distinguished provider by MediFind in the treatment of MAGIC Syndrome. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration.

Yousef Khelfa
Experienced in MAGIC Syndrome
Dr. Yousef Khelfa
Oncology
Experienced in MAGIC Syndrome
Dr. Yousef Khelfa
Oncology

Stockton Medical Plaza II

2545 West Hammer Lane, 
Stockton, CA 
 (60.8 miles away)
209-955-3050
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Yousef Khelfa is an Oncologist in Stockton, California. Dr. Khelfa is rated as a Distinguished provider by MediFind in the treatment of MAGIC Syndrome. His top areas of expertise are Neuroendocrine Tumor, Paget Disease of the Breast, Breast Cancer, and Thrombocytopenia. Dr. Khelfa is currently accepting new patients.

Experienced in MAGIC Syndrome
Dr. Arpeet T. Shah
Oncology | Hematology | Hematology Oncology
Experienced in MAGIC Syndrome
Dr. Arpeet T. Shah
Oncology | Hematology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arpeet Shah is an Oncologist and a Hematologist in Stanford, California. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of MAGIC Syndrome. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Blood Clots, Thrombocytopenia, and Nephrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Liedtke's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 12 Advanced Conditions
View All 88 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile